

1 **DOI: <https://doi.org/10.47391/JPMA.552>**

2
3 **Obstetric outcomes of HIV positive mothers in tertiary care**
4 **hospital**

5
6 **Shahida Husain Tarar¹, Muhammad Afzal², Hamna Atta³, Syed**
7 **Muhammad Ali Shah⁴**

8 **1** Department of Gynaecology and Obstetrics, Nawaz Sharif Medical College, Gujrat,

9 Pakistan; **2** Department of Medicine, Nawaz Sharif Medical College, Gujrat, Pakistan;

10 **3** Department of Gynaecology and Obstetrics, DHQ Hospital, Rawalpindi, Pakistan;

11 **4** Department of Medicine, Aziz Bhatti Shaheed Teaching Hospital, Gujrat, Pakistan

12 **Correspondence:** Syed Muhammad Ali Shah **Email:**syedmuhammadalishah5@gmail.com

13
14 **Abstract**

15 **Objective:** To evaluate the pregnancy outcome of human immunodeficiency
16 syndrome-positive mothers.

17 **Method:** The prospective observational study was conducted at the Department
18 of Gynaecology and Obstetrics, Aziz Bhatti Shaheed Teaching Hospital, Gujrat,
19 Pakistan, from June 2011 to March 2018, and comprised pregnant women
20 screened positive for human immunodeficiency syndrome. Risk factors and
21 perinatal outcomes were noted on a predesigned proforma. Data was analysed
22 using SPSS 20.

23 **Results:** Of the 74 subjects with a mean age of 29 ± 5.27 years, 63(85.1%) were
24 multiparous and 11(14.9%) were nulliparous. Major risk factors included
25 unsterilized nasal or ear piercing in 70(94.6%) subjects, history of blood
26 transfusion 57(77%) and history of dental procedure in unsterilized settings
27 23(31.1%). Spouses of 43(58.1%) subjects were positive for human
28 immunodeficiency syndrome, 22(29.7%) were negative and 9(12.2%) had

29 unknown status in this regard. In terms of outcome, 12(16.3%) subjects had
30 spontaneous abortion, 11(12.2%) had intrauterine death of foetus, 6(8.1%) had
31 preterm delivery and 45(60.8%) reached full term and were delivered. There
32 were 2(2.6%) patients with stage 4 disease who died during pregnancy.

33 **Conclusion:** Human immunodeficiency syndrome infection in pregnant women
34 was found to be associated with poor pregnancy outcome.

35 **Key Words:** HIV, Pregnancy, Pakistan, Perinatal, Risk factors.

36

37 **Introduction**

38 Human immunodeficiency virus (HIV) is a major health problem worldwide
39 and estimated 36.7 million people were infected with it till the end of 2016. It is
40 mainly present in developed countries and Africa, and has claimed almost 1
41 million lives due to acquired immunodeficiency syndrome (AIDS)-related
42 problems.¹ The prevalence of HIV in Pakistan is relatively low. It is estimated
43 that 0.13 million people are infected with HIV in Pakistan, and only 8,900
44 people are on anti-retroviral therapy (ART). Out of 0.13 million, 40,000
45 women of child-bearing age (>15-49 years) are infected and a mere fraction of
46 almost 5% (1900) are estimated to be taking ART ². It has the highest
47 prevalence in injection drug users (IDUs) in Pakistan (21%)² and, according to a
48 survey by World Bank in 2012, HIV was present in almost 50% IDUs in Gujrat
49 district³.

50 The risk factors for HIV transmission include blood transfusion, vertical
51 exposure, sexual exposures, and other parenteral exposures in a descending
52 order⁴. Pregnancies in HIV-positive mothers are associated with poor
53 outcomes⁵. The effects of HIV on pregnancy include spontaneous abortion,
54 stillbirth, preterm delivery and death of mother⁶.

55 The World Health Organisation (WHO) guidelines⁷ suggest the initiation of
56 ART in all pregnant mothers regardless of their clinical stage and cluster of
57 differentiation 4 (CD4) count, and should be continued lifelong. The current first-line

58 regimen for HIV treatment in adults, including pregnant females, include
59 tenfovir disoproxil fumarate (TDF), lamuvidine (3TC) and efavirenz (EFV).
60 Similarly, infant prophylaxis should be given to high-risk infants born to HIV-
61 positive mothers as mother-to-child transmission is very high at 7 out of 10. It
62 reduces long-term morbidity, and enhances infant immune response in infants.
63 Current first-line drugs include ziduvudine (ZID; twice daily) and nevirapine
64 (NVP; once daily) for the first 6 weeks.

65 There are no current studies available on perinatal outcome in mothers having
66 HIV infection in Pakistan. As the estimated prevalence of HIV is low, few
67 pregnant patients are encountered in daily practice who need a patient-centred
68 approach for the wellbeing of mothers as well as infants born to HIV-positive
69 mothers. Although there is low prevalence of HIV reported in women of child-
70 bearing age, many cases go unreported due to social stigmata of being HIV-
71 positive, and unawareness about the problems associated with it². There is a
72 need for research in HIV-positive pregnant females. The current study was
73 planned to meet that need by assessing the pregnancy outcome in HIV-positive
74 mothers.

75

76 **Subjects and methods**

77 The observational cross-sectional study was conducted at the Department of
78 Gynaecology and Obstetrics, Aziz Bhatti Shaheed Teaching Hospital, Gujrat,
79 Pakistan, from June 2011 to March 2018.

80 After approval from the institutional ethics review committee, the sample size
81 was calculated keeping frequency of stillbirth in pregnancy 3.3%⁸ and using
82 OpenEpi calculator while keeping 95% confidence interval (CI) and 5% margin
83 of error.⁹ After taking informed consent, all patients booked after pregnancy
84 were screened for HIV using routine screening at their first visit. Patients who
85 were already on ART or who were newly diagnosed during the screening itself
86 were included using non-probability consecutive sampling.

87 All the women who were screened HIV-positive were counselled and the
88 diagnosis was further confirmed by enzyme-linked immunosorbent assay
89 (ELISA) for HIV. CD4 counts were checked and patients were classified into
90 different stages using the WHO classification¹⁰.

91 Those who were already on ART continued it, while the newly-diagnosed
92 patients were started ART as per the WHO recommendations during
93 pregnancy¹⁰. ART used was combination single daily dose of 3TC 150mg, ZID
94 300mg and NEV 200mg (Duovir-N). Those patients who presented and were
95 diagnosed with HIV at the time of labour were started ART post-partum. No
96 intrapartum ART was given due to unavailability of infusions form. Duration
97 and time of initiation of ART was noted in all patients.

98 Detailed history was taken regarding risk factors of HIV. Risk factors included
99 were spouse working abroad, history of working as sex worker, history of
100 unsterilized nasal or ear piercing, history of IDU in patient and spouse, and
101 history of blood transfusion in patients. Patients and their spouses were enquired
102 about their HIV status. All patients were followed during pregnancy and
103 outcomes of pregnancy were noted. Mode of delivery and place of delivery
104 were noted in patients who reached full-term pregnancy. Gender of neonates
105 delivered was also noted.

106 Foetal death >20 weeks of gestation was considered intrauterine death IUD).
107 Patients were considered to have preterm delivery when they were delivered
108 before reaching 37 weeks of pregnancy. Caesarean section (CS) was performed
109 when there was either foetal or maternal distress or some mechanical
110 obstruction to spontaneous vaginal delivery (SVD) or patients who did not
111 receive ART during pregnancy and those mothers having viral load >1000
112 copies/ml or unknown at the time of delivery.

113 Patients were counselled regarding breastfeeding of neonates and contraceptive
114 methods were advised. Neonates were started ART prophylaxis using NEV
115 drops orally once daily and referred to HIV centre of the hospital for follow-up.

116 Patients were followed for 3 months postpartum and condition of patients and
117 infants, mode of infant feeding, and use of contraceptives were enquired and
118 noted. Data was collected on a predesigned proforma, and was analysed using
119 SPSS 20. Continuous variables, like age and duration of ART, were expressed
120 as mean \pm standard deviation (SD). Categorical variables, such as risk factors
121 and HIV status of spouse, were expressed as frequencies and percentages.

122

123 **Results**

124 Of the 74 married subjects with a mean age of 29 ± 5.27 years, 63(85.1%) were
125 multiparous and 11(14.9%) were nulliparous. Mean CD4 count was
126 $573\pm 234/\text{mm}^3$ (Table 1).

127 Major risk factors included unsterilized nasal or ear piercing in 70(94.6%)
128 subjects, history of blood transfusion 57(77%) and history of dental procedure
129 in unsterilised settings 23(31.1%). Spouses of 43(58.1%) subjects were HIV-
130 positive, 22(29.7%) were HIV-negative and 9(12.2%) had unknown HIV status
131 (Table 2).

132 In terms of outcome, 12(16.3%) subjects had spontaneous abortion, 11(12.2%)
133 had IUD of foetus, 6(8.1%) had preterm delivery and 45(60.8%) reached full
134 term and were delivered (Table 3). There were 2(2.6%) patients with stage 4
135 disease who died during pregnancy.

136 ART was started during pregnancy in 64(86.5%) patients. Of them, 9(12.2%)
137 were already diagnosed but not on ART, while 55(74.3%) were newly
138 diagnosed. Also, 2(2.7%) patients who were already diagnosed and taking ART,
139 while 8(10.8%) presented at the time of labour and were started ART
140 postpartum. Mean duration of ART in patients who presented during pregnancy
141 was 134.74 ± 82.76 days while those who were already on treatment had mean
142 duration of treatment of 318.5 ± 9.19 days. According to WHO classification,
143 5(6.7%) patients had stage 1, 58(78.4%) stage 2, 7(9.5%) stage 3 and 4(5.4%)
144 patients had stage 4 disease.

145 Those reaching full term were delivered in hospital. Of them, 30(58.8%) had CS
146 and 21(41.2%) SVDs. Overall, 50(98%) patients had singleton pregnancy and
147 1(2%) had twin pregnancy. Besides, there were 24(46.2%) boys and 28(53.8%)
148 girls.

149 In patients who delivered, 44(86%) were stable, 5(9.8%) were lost to follow-up
150 and 2(3.92%) died during the follow-up period. The overall mortality, as such,
151 was 4(5.4%).

152 While all the remaining 44(100%) patients who came for follow-up were
153 adherent to the use of condom as a contraceptive, feeding option of top feed was
154 adopted by only 20(45.45%) patients and 24(54.55%) adopted breastfeeding
155 despite the counselling.

156

157 **Discussion**

158 Although the reported prevalence rate of HIV infection in Pakistan is 0.1 in
159 adults and <0.1 in women of child-bearing age³, there might be a large number
160 of undiagnosed HIV infection which is the case even in the developed
161 countries¹¹ like the United States. Social dilemma associated with diagnosis of
162 HIV further increases the woes of patients, and leads to under-reporting and
163 complications associated with HIV. As depicted in the current study, a few
164 patients despite diagnosis were not taking ART. Although rare among females
165 of child-bearing age, the current study demonstrates the problems which can
166 present in such women in our country where research data is scarce regarding
167 this issue.

168 Although screening is necessary in all females at booking visit¹⁰, there is lack of
169 awareness regarding booking and its benefits in our country. Early booking can
170 lead to early diagnosis and treatment of HIV. Diagnosis of HIV before
171 pregnancy and initiation of ART potentially leads to better outcome of
172 pregnancy¹². Antenatal ART also reduces the transmission of HIV to infants¹³.

173 Multiple risk factors are associated with transmission of HIV. There are no
174 studies done in the country addressing the risk factors of HIV transmission
175 among women of child-bearing age. Nasal and ear piercing is a common
176 practice which is done mainly in unsterilized settings. The same needles are
177 usually used which pose a major risk factor for HIV transmission as shown in
178 the current study. Dental procedures from quacks are also a potential threat
179 towards the spread of HIV. Blood transfusion is considered a major risk factor
180 for HIV transmission⁴.

181 This None of the patients in the current study had a history of IV drug abuse or
182 working as sex worker. WHO data shows that prevalence among sex workers
183 and IV drug abusers is 3.8% and 21% respectively³. A small number of spouses
184 of these patients had history of IV drug abuse and were living abroad where
185 they might have been exposed to unprotected sex.

186 One of major risk factors identified by the current study was prevalence of HIV
187 in spouse (58.1%). There was no information available regarding transmission
188 husband-to-wife or wife-to-husband. There is lack of knowledge about HIV in
189 Pakistani mothers. A study showed that more than half the mothers had
190 absolutely no idea of HIV¹⁴. Lack of knowledge of HIV in women and sero-
191 positivity of spouse also pose a major risk of transmission, although rate of
192 sexual transmission of HIV is very low⁴. A study in Faisalabad regarding risk
193 factors of HIV in sero-positive patients showed IV drug abuse as the major risk
194 factor followed by blood transfusion and sexual transmission¹⁵.

195 The current study showed only 60.8% pregnancies in HIV-positive mothers
196 reaching full term and maternal mortality of 5.4%. A meta-analysis showed
197 increased incidence of stillbirths and pre-term delivery in patients infected with
198 HIV¹⁶ which is also evident in the current study. A recent study in a large
199 sample of HIV-positive women in India reported pregnancy wastage in 17%
200 mothers, including stillbirths (3.8%), spontaneous abortions (13.7%) and
201 induced abortions (2.8%)¹⁷. These figures are comparable to the current study in

202 case of spontaneous abortions (13.7% vs 16.3%), but the rate of stillbirths was
203 higher and none of patients had induced abortion. These differences may be due
204 to a small sample size and inadequate ART in the current study. Another large
205 study demonstrated stillbirths 3.3% (vs 12.2%) and preterm delivery in 19.6%
206 (vs 16.3%).⁸ This may also be due to different sample sizes.

207 The mortality rates of the current study reported are comparable with those
208 reported earlier¹⁸. To the best of our knowledge, the current study is a pioneering
209 effort in the country. However it had a small sample size which was collected
210 over 7 years due to low prevalence rate of HIV in women of child-bearing age³.
211 Tenofovir-based ART was used which has been reported safe in pregnancy and
212 for neonates¹⁹. Data regarding mother-to-child transmission was not collected,
213 but infant prophylaxis was advised. It also showed poor adherence to
214 counselling regarding breastfeeding.

215 The outcome of pregnancy in HIV-positive women can be improved by
216 decreasing the social stigmata associated with HIV, improving knowledge about
217 HIV and benefits of ART. Integrating maternal health with HIV services may
218 reduce the adverse maternal and neonatal outcomes²⁰. Further large-scale
219 studies are needed in this regard.

220

221 **Conclusion**

222 HIV infection in pregnant women was found to be associated with poor
223 pregnancy outcome.

224

225 **Disclaimer:** None.

226 **Conflict of interest:** None.

227 **Source of Funding:** None.

228

229

230

231 **References**

- 232 1. WHO HIV/AIDS Factsheet 2017. Available at
233 <http://www.who.int/mediacentre/factsheets/fs360/en/> last accessed on 25
234 March 2018.
- 235 2. WHO Country Factsheet Pakistan 2016 available at
236 <http://www.unaids.org/en/regionscountries/countries/pakistan> last
237 accessed on 25 March 2018.
- 238 3. HIV/AIDS in Pakistan. Available at
239 <http://www.worldbank.org/en/news/feature/2012/07/10/hiv-aids-pakistan>
240 last accessed on 25 March 2018.
- 241 4. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J.
242 Estimating per-act HIV transmission risk: a systematic review. *AIDS*.
243 2014;28:1509–1519. DOI: [10.1097/QAD.0000000000000298](https://doi.org/10.1097/QAD.0000000000000298).
- 244 5. Arab K, Spence AR, Czuzoj-Shulman N, Abenhaim HA. Pregnancy
245 outcomes in HIV-positive women: a retrospective cohort study. *Arch*
246 *Gynecol Obstet* 2017;295(3):599–606 DOI: [10.1007/s00404-016-4271-y](https://doi.org/10.1007/s00404-016-4271-y)
- 247 6. Gautam S, Shah T. Study of perinatal outcome in human
248 immunodeficiency virus positive women. *Int J Reprod Contracept Obstet*
249 *Gynecol*. 2016;5(8):2587-2591 DOI: [http://dx.doi.org/10.18203/2320-](http://dx.doi.org/10.18203/2320-1770.ijrcog20162627)
250 [1770.ijrcog20162627](http://dx.doi.org/10.18203/2320-1770.ijrcog20162627)
- 251 7. WHO Consolidated Guidelines On The Use Of Antiretroviral Drugs For
252 Treating And Preventing HIV Infection 2016 Recommendations For A
253 Public Health Approach. Second Edition. Available at
254 [http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_](http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf;jsessionid=375920B0EB562009B1A689DC36B22C12?sequence=1)
255 [eng.pdf;jsessionid=375920B0EB562009B1A689DC36B22C12?sequence](http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf;jsessionid=375920B0EB562009B1A689DC36B22C12?sequence=1)
256 [=1](http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf;jsessionid=375920B0EB562009B1A689DC36B22C12?sequence=1) last accessed on 25 March 2018.
- 257 8. Chen JY, Ribaud HJ, Souda S, Parekh N, Ogwu A, Lockman S. et al.
258 Highly active antiretroviral therapy and adverse birth outcomes among

- 259 HIV-infected women in Botswana. *J Infect Dis.* 2012;206(11):1695–
260 1705. doi:10.1093/infdis/jis553
- 261 9. OpenEpi Sample Size Calculator available at:
262 <http://www.openepi.com/SampleSize/SSCC.htm> last accessed on 23rd
263 April 2020
- 264 10. WHO Consolidated guidelines on the use of antiretroviral drugs for
265 treating and preventing HIV infection. available at
266 <https://www.who.int/hiv/pub/guidelines/arv2013/download/en/> last
267 accessed on 09 August 2019
- 268 11. Hall HI, An Q, Tang T, Song R, Chen M, Green T, et al. Prevalence of
269 Diagnosed and Undiagnosed HIV Infection--United States, 2008-2012.
270 *Morb Mortal Wkly Rep.* 2015;64(24):657-62.
- 271 12. Momplaisir FM, Brady KA, Fekete T, Thompson DR, Diez Roux A,
272 Yehia BR. Time of HIV Diagnosis and Engagement in Prenatal Care
273 Impact Virologic Outcomes of Pregnant Women with HIV. *PLoS ONE.*
274 2015;10(7): e0132262. doi:10.1371/journal.pone.0132262
- 275 13. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al.
276 Benefits and risks of antiretroviral therapy for perinatal HIV prevention.
277 *N Engl J Med* 2016;375:1726-37. DOI: 10.1056/NEJMoa1511691
- 278 14. S Zaheer, SK Aslam, K Shafique. Inequalities in HIV knowledge among
279 Pakistani mothers: Results from Demographic Health Survey 2012-
280 13 *Eur. J. Public Health*;
281 2016;(26),suppl1;ckw172.077, <https://doi.org/10.1093/eurpub/ckw172.07>
282 7
- 283 15. Maan MA, Hussain F, Jamil M. Prevalence and risk factors of HIV in
284 Faisalabad, Pakistan—a retrospective study. *Pakistan J Med Sci*
285 2014;30:32–5. DOI: [10.12669/pjms.301.4176](https://doi.org/10.12669/pjms.301.4176)
- 286 16. Brocklehurst, P., French, R. The association between maternal HIV
287 infection and perinatal outcome: a systematic review of the literature and

- 288 meta-analysis. Br J Obstet Gynaecol. 1998;105:836–848. DOI:
289 10.1111/j.1471-0528.1998.tb10227.x
- 290 17.Halli SS, Khan CGH, Shah I, Washington R, Isaac S, Moses S et al.
291 Pregnancy wastage among HIV infected women in a high HIV
292 prevalence district of India. BMC Public Health 2015; 15:602. DOI:
293 10.1186/s12889-015-1965-1
- 294 18.Ezechi OC, Gab-Okafor CV, Oladele DA, Kalejaye OO, Oke BA, Ujah
295 IO. Pregnancy, obstetric and neonatal outcomes in HIV positive Nigerian
296 women. Int J Gynecol Obstet. 2013;119:S345
- 297 19.Nachega JB, Uthman OA, Mofenson LM, Anderson JR, Kanters
298 S, Renaud F et al. Safety of Tenofovir Disoproxil Fumarate–Based
299 Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women
300 and Their Infants: A Systematic Review and Meta-Analysis. J Acquir
301 Immune Defic Syndr. 2017;76(1):1-12.
302 doi:10.1097/QAI.0000000000001359.
- 303 20.Hodgson I, Plummer ML, Konopka SN, Colvin CJ, Jonas E, Albertini J.
304 et al. A Systematic Review of Individual and Contextual Factors
305 Affecting ART Initiation, Adherence, and Retention for HIV-Infected
306 Pregnant and Postpartum Women. PLoS ONE 2014;9(11): e111421.
307 doi:10.1371/journal.pone.0111421

308 -----
309
310
311 **Table 1: Patient Characteristics**

Patients' Characteristics	Number	Percentage
Number of Patients (n)	74	100%
Mean Age (years)	29±5.27	-
Parity		
• Multiparous	63	85.1%
• Nulliparous	11	14.9%

HIV Status		
<ul style="list-style-type: none"> • Known • Unknown 	41 33	55.41% 45.59%
Mean CD4 Count (mm ⁻³)	573±234	-
Initiation of ART		
<ul style="list-style-type: none"> • Before Pregnancy • During Pregnancy • After Pregnancy 	2 64 8	2.7% 86.5% 10.8%
Mean duration of ART (days)	134.74±82.76	-
WHO Disease Stage		
<ul style="list-style-type: none"> • Stage 1 • Stage 2 • Stage 3 • Stage 4 	5 58 7 4	6.7% 78.4% 9.5% 5.4%

312 CD4: Cluster of differentiation 4; ART: Anti-retroviral therapy; WHO: World Health Organisation.

313

314 -----

315

316

Table 2: Frequency of Risk factors of HIV in sample population

Risk Factor	Number	Percentage
Unsterilized nasal or ear piercing	70	94.6%
Blood transfusion	57	77%
Dental procedure in unsterilized settings	23	31.1%
Spouse using IV drugs	8	10.8%
Spouses working abroad.	6	8.1%
HIV Status of Spouse		
<ul style="list-style-type: none"> • HIV positive • HIV negative 	43	58.1%

• Unknown HIV status	22	29.7%
	9	12.2%
History of IV drug abuse	0	0%
Worked as sex-worker	0	0%

317 HIV: Human immunodeficiency syndrome; IV: Intravenous

318

319 -----

320

321 **Table 3: Maternal Outcomes in Human immunodeficiency syndrome (HIV) Positive**
 322 **Mothers.**

Pregnancy Outcome	Number	Percentage
Spontaneous abortion	12	16.3%
Intrauterine death (IUD)	11	12.2%
Preterm delivery	6	8.1%
Full term delivery	45	60.8%

323

Provisionally Accepted for Publication